Literature DB >> 32321013

Plasma miR-1273g-3p acts as a potential biomarker for early Breast Ductal Cancer diagnosis.

Huan Guo1,2, Xiangting Zeng3, Haining Li2, Yanxiang Guo2, Tao Wang2, Hongyun Guo2, Gongjian Zhu2, Lan Wang2, Haihong Zhou2, Kedan Liu2, Xiaoyi Chen2, Haitao Wang2, Xinke Zhao4, Haixiang Su2,4, Yingdong Li1,4.   

Abstract

Circulating miRNAs presenting in plasma in a stable manner have been demonstrated their potential role as a promising biomarkers in many human diseases, such as Alzheimer's disease, melanoma and ovarian carcinoma. However, few circulating miRNAs could be used for breast ductal cancer diagnosis. Here, we identified miR-1273g-3p as a biomarker for detecting breast ductal cancer. We detected miR-1273g-3p levels in the plasma of 39 sporadic breast ductal cancer patients and 40 healthy donors by Stem-loop Quantitative Real-time PCR (qRT-PCR). The results showed the plasma miR-1273g-3p level were significantly up-regulated in breast ductal cancer patients compared with healthy donors (p=0.0139). Receiver operating characteristic (ROC) curve also revealed the significantly diagnostic ability of miR-1273g-3p in patients (p=0.0414). In addition, the plasma level of miR-1273g-3p was closely related to IIIB-IIIC TNM stage. We also confirmed the higher expression level of miR-1273g-3p in breast cancer cell lines MCF-7 (4.872±0.537) than normal breast cells (Hs 578Bst). Taken together, miR-1273g-3p could represent as a potential biomarker for early breast ductal cancer diagnosis.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32321013     DOI: 10.1590/0001-3765202020181203

Source DB:  PubMed          Journal:  An Acad Bras Cienc        ISSN: 0001-3765            Impact factor:   1.753


  5 in total

1.  MiR-1273 g-3p Promotes Malignant Progression and has Prognostic Implications in Prostate Cancer.

Authors:  Yaxue Chang; Qian Deng; Zhenfeng Guan; Yongyi Cheng; Yi Sun
Journal:  Mol Biotechnol       Date:  2021-08-24       Impact factor: 2.695

2.  Meta-analysis of diagnostic cell-free circulating microRNAs for breast cancer detection.

Authors:  Emir Sehovic; Sara Urru; Giovanna Chiorino; Philipp Doebler
Journal:  BMC Cancer       Date:  2022-06-09       Impact factor: 4.638

Review 3.  A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research.

Authors:  Cameron Brown; Michael Mantzaris; Elpiniki Nicolaou; Georgia Karanasiou; Elisavet Papageorgiou; Giuseppe Curigliano; Daniela Cardinale; Gerasimos Filippatos; Nikolaos Memos; Katerina K Naka; Andri Papakostantinou; Paris Vogazianos; Erietta Ioulianou; Christos Shammas; Anastasia Constantinidou; Federica Tozzi; Dimitrios I Fotiadis; Athos Antoniades
Journal:  Cardiooncology       Date:  2022-09-07

Review 4.  miRNA Expression Profiles in Luminal A Breast Cancer-Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment.

Authors:  Erik Kudela; Marek Samec; Lenka Koklesova; Alena Liskova; Peter Kubatka; Erik Kozubik; Tomas Rokos; Terezia Pribulova; Eva Gabonova; Marek Smolar; Kamil Biringer
Journal:  Int J Mol Sci       Date:  2020-10-17       Impact factor: 5.923

5.  Identification of Flap Endonuclease 1 With Diagnostic and Prognostic Value in Breast Cancer.

Authors:  Min Wu; Pan Zhang; Penghui Wang; Zhen Fang; Yaqin Zhu
Journal:  Front Oncol       Date:  2021-06-30       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.